Table 3.
Cases of PJI treated with dalbavancin according to the surgical strategy adopted (data from Buzón et al., Tobudic et al., and Wunsch et al.).
| DAIR (n = 2) |
Prosthesis Removal (n = 27) |
Implant Retention and Suppressive Treatment (n = 7) | All Patients (n = 36) |
|
|---|---|---|---|---|
| Sex (female) | 1 (50%) | 11 (40.7%) | 3 (42%) | 15 (43%) |
| Age *,1 (years) | 69 (67–71) | 69 (18–87) | 62 (15–92) | 67 (15–92) |
| Number of surgeries before DAL | 1 | 2 (1–4) | 2.5 (1–3) | 1.8 (1–4) |
| Treatments | ||||
| DAL alone | 2 (100%) | 11 (40.7%) | 5 (71%) | 18 (50%) |
| DAL + rifampin | 0 | 7 (26%) | 2 | 9 (25%) |
| DAL + other treatments | 0 | 9 (30%) | 0 | 9 (25%) |
| Etiology | ||||
| S. aureus 2 | 0 | 5 (18.5%) | 1 (14%) | 6 (17%) |
| CoN staphylococci | 2 (100%) | 6 (22.2%) | 2 (29%) | 10 (28%) |
| Enterococcus spp 3 | 0 | 4 (14.8%) | 1 (14%) | 5 (14%) |
| Anaerobic GP | 0 | 1 (3.7%) | 0 | 1 (3%) |
| Other GP | 0 | 2 (29%) | 2 (6%) | |
| Mixed GP | 0 | 10 (37%) | 10 (28%) | |
| Unknown etiology | 0 | 1 (14%) | 1 (3%) | |
| Outcome (Success) | 1 (50%) | 25 (93%) | 4 (57%) 4 | 29 (81%) |
| Follow up (months) *,1 | 4 (2–6) | 16 (3–40) | 6 (3–14) | 14 (2–40) |
* Continuous variables are expressed as median and (range). 1 Data available for 20 patients. 2 There were 4 methicillin-susceptible strains (3 managed with prosthesis removal and 1 by suppressive antimicrobial therapy), and 2 methicillin-resistant strains (both managed by prosthesis removal). 3 There were 4 E. faecium (all treated with prosthesis removal) and 1 E. faecalis (treated with suppressive antimicrobial treatment). 4 One patient died to unrelated causes after three months with no clinical or biochemical signs of failure. Abbreviations: DAL: dalbavancin. CoN: coagulase-negative. GP: Gram-positives. DAIR: debridement, antibiotics, and implant retention.